UNSPSC 51263106: Carteolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NF31401XG, chemically known as 2(1h)-quinolinone, 5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro- but generally known as carteolol, which bears US NIH Compound Identifier 2583. Carteolol most often comes in base and hydrochloride forms. European Medicines Agency schedules Carteolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06150MIG.

UNSPSC 51263106 Carteolol, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The recent opportunity posted by Seminole County, Florida solicits naloxone and safe drug deactivation systems—neither of which is carteolol, a beta-blocker pharmaceutical used to treat glaucoma and hypertension. The mismatch suggests either a classification error in the county's procurement database or that the code is not actively used for its nominal pharmaceutical scope in current state and local contracting. The source contains no additional opportunities under this code to establish a pattern of actual purchasing activity.

Without recent relevant opportunities to characterize issuing-body mix, geographic spread, or representative work, no further analysis is possible. If carteolol procurement occurs in state and local markets, it is not surfacing in current solicitation notices under this UNSPSC designation.